Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


New HTA budget impact guidelines must not dissuade industry from investing in Ireland, says IPHA

This article was originally published in Scrip

Executive Summary

As the Irish government steels itself to request the European Union and the International Monetary Fund for a bailout of up to €90 billion to prop up its debt ridden banks, the Irish pharmaceutical industry association (IPHA) has cautioned against measures that might threaten international pharma investors. In particular, IPHA warns that new health technology appraisal guidelines published today on budget impact analysis (BIA) must not "result in any inadvertent delay in patient access to new health technologies" or dissuade companies from launching in Ireland.






Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts